27.25
Staar Surgical Co stock is traded at $27.25, with a volume of 867.61K.
It is up +2.14% in the last 24 hours and down -1.62% over the past month.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
See More
Previous Close:
$26.68
Open:
$26.87
24h Volume:
867.61K
Relative Volume:
0.55
Market Cap:
$1.34B
Revenue:
$224.45M
Net Income/Loss:
$-95.27M
P/E Ratio:
-14.12
EPS:
-1.93
Net Cash Flow:
$-43.74M
1W Performance:
+1.57%
1M Performance:
-1.62%
6M Performance:
+62.30%
1Y Performance:
-13.79%
Staar Surgical Co Stock (STAA) Company Profile
Name
Staar Surgical Co
Sector
Industry
Phone
(626) 303-7902
Address
1911 WALKER AVE, MONROVIA, CA
Compare STAA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
STAA
Staar Surgical Co
|
27.25 | 1.32B | 224.45M | -95.27M | -43.74M | -1.93 |
![]()
ISRG
Intuitive Surgical Inc
|
435.73 | 154.00B | 9.15B | 2.63B | 1.99B | 7.1661 |
![]()
BDX
Becton Dickinson Co
|
186.66 | 53.47B | 21.39B | 1.61B | 2.55B | 5.5609 |
![]()
RMD
Resmed Inc
|
273.01 | 39.70B | 5.15B | 1.40B | 1.65B | 9.5082 |
![]()
ALC
Alcon Inc
|
72.60 | 35.62B | 10.03B | 1.07B | 1.39B | 2.1549 |
![]()
WST
West Pharmaceutical Services Inc
|
262.47 | 18.82B | 2.96B | 487.70M | 344.00M | 6.6758 |
Staar Surgical Co Stock (STAA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-21-25 | Initiated | Wells Fargo | Equal Weight |
Feb-12-25 | Downgrade | BTIG Research | Buy → Neutral |
Feb-12-25 | Downgrade | Jefferies | Buy → Hold |
Feb-12-25 | Downgrade | Mizuho | Outperform → Neutral |
Feb-12-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Jul-15-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jun-11-24 | Upgrade | BTIG Research | Neutral → Buy |
Mar-11-24 | Upgrade | Stifel | Hold → Buy |
Dec-05-23 | Downgrade | Needham | Buy → Hold |
Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
Sep-15-23 | Downgrade | The Benchmark Company | Buy → Hold |
Aug-03-23 | Downgrade | Canaccord Genuity | Buy → Hold |
Jun-07-23 | Downgrade | William Blair | Outperform → Mkt Perform |
Apr-17-23 | Initiated | Piper Sandler | Neutral |
Feb-06-23 | Downgrade | BTIG Research | Buy → Neutral |
Dec-28-22 | Reiterated | BTIG Research | Buy |
Dec-08-22 | Initiated | Stifel | Hold |
Nov-07-22 | Upgrade | Sidoti | Neutral → Buy |
Oct-14-22 | Resumed | Stephens | Overweight |
Oct-13-22 | Initiated | Mizuho | Buy |
Apr-08-22 | Initiated | Needham | Buy |
Mar-28-22 | Upgrade | The Benchmark Company | Hold → Buy |
Mar-18-22 | Upgrade | BTIG Research | Neutral → Buy |
Jul-09-21 | Initiated | Oppenheimer | Perform |
Jan-19-21 | Downgrade | The Benchmark Company | Buy → Hold |
Oct-26-20 | Downgrade | Sidoti | Buy → Neutral |
Aug-31-20 | Upgrade | Sidoti | Neutral → Buy |
Aug-06-20 | Reiterated | The Benchmark Company | Buy |
Jul-06-20 | Downgrade | Sidoti | Buy → Neutral |
Jun-24-20 | Downgrade | BTIG Research | Buy → Neutral |
Jun-15-20 | Initiated | Jefferies | Buy |
Dec-04-19 | Initiated | BTIG Research | Buy |
Sep-24-18 | Reiterated | The Benchmark Company | Buy |
Aug-06-18 | Resumed | The Benchmark Company | Buy |
Nov-20-17 | Reiterated | The Benchmark Company | Buy |
Aug-14-17 | Reiterated | The Benchmark Company | Buy |
Mar-03-17 | Reiterated | The Benchmark Company | Buy |
May-18-16 | Upgrade | The Benchmark Company | Hold → Buy |
Sep-10-13 | Resumed | The Benchmark Company | Buy |
Feb-28-13 | Reiterated | The Benchmark Company | Buy |
Nov-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
Mar-02-12 | Initiated | Northland Securities | Outperform |
Oct-25-11 | Reiterated | The Benchmark Company | Buy |
Oct-12-10 | Initiated | Morgan Joseph | Buy |
May-11-10 | Initiated | Benchmark | Buy |
View All
Staar Surgical Co Stock (STAA) Latest News
Large Staar Holders Oppose $1.5B Sale - Orange County Business Journal
Broadwood slams STAAR board over “carelessness” in Alcon sale defense By Investing.com - Investing.com Canada
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates STAA, GES, SMLR on Behalf of Shareholders - GlobeNewswire Inc.
Investor Group Opposes Alcon's Acquisition of STAAR Surgical (AL - GuruFocus
Broadwood issues letter to Staar Surgical board questioning ‘rush’ in Alcon sale - TipRanks
Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale - MarketScreener
Will STAAR Surgical Company benefit from macro trendsWeekly Trend Summary & Stock Portfolio Risk Management - newser.com
STAAR Surgical holders should vote against sale to Alcon, Glass Lewis says - MSN
Global Myopia Treatment Devices Market Poised for Strong Growth at a CAGR of ~8% by 2032, Driven by Technological Innovations and Increasing Eye Care Demand | DelveInsight - GlobeNewswire
Glass Lewis recommends against STAAR–Alcon merger, bolstering Broadwood’s campaign - Investing.com
Live market analysis of STAAR Surgical CompanyMarket Movers & Real-Time Chart Breakout Alerts - newser.com
STAAR Surgical (STAA): A Fresh Look at Valuation Following Recent Share Price Cooldown - simplywall.st
Glass Lewis Issues Recommendations to Shareholders of STAAR Surgical Company - MarketScreener
STAAR Surgical Board Defends $1.5 Billion Alcon Acquisition Plan - Finimize
AI Insurance Is Expensive - Bloomberg.com
Alcon (ALC) Faces Opposition in Staar Surgical Merger Deal - GuruFocus
STAAR urges shareholders to approve Alcon merger despite Glass Lewis report - Investing.com India
STAAR Surgical (STAA): Proxy Adviser Urges Rejection of Alcon De - GuruFocus
Glass Lewis Advises Against Alcon (ALC) Acquisition of STAAR - GuruFocus
STAAR Surgical Provides Information to Shareholders - MarketScreener
Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon - MarketScreener
Defender Capital Opposes STAAR Surgical's Proposed Acquisition By Alcon - Nasdaq
Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon - Stock Titan
STAAR Surgical’s Long-Term Shareholder Says Proposed Deal With Alcon Undervalues The Company - Stocktwits
STAAR shareholders urged to vote for Alcon merger with 59% premium - Investing.com Canada
Yunqi Capital opposes sale of STAAR Surgical to Alcon - Investing.com
Yunqi Capital opposes sale of STAAR Surgical to Alcon By Investing.com - Investing.com Nigeria
Yunqi Capital, One of STAAR Surgical Company’s Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon - The Joplin Globe
$62/Share Offer Challenged: STAAR Shareholder Yunqi (5.1%) Reiterates Opposition Ahead of Vote - Stock Titan
STAAR Surgical Faces Shareholder Clash Over Alcon Buyout - Finimize
Broadwood urges STAAR shareholders to reject $28 per share Alcon deal - Investing.com
Broadwood urges shareholders to vote against proposed acquisition of STAAR by Alcon - MarketScreener
Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Judgment in Proposed Sale to Alcon - Stock Titan
STAAR Surgical Addresses Broadwood Partners’ Flawed, Misleading, and Misinformed Claims - MarketScreener
STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis - Business Wire
59% premium to 90-day VWAP: STAAR Surgical backs $28 Alcon merger and urges stockholders to vote - Stock Titan
Major STAAR Surgical Investors Push Back On Alcon Acquisition - Finimize
STAAR Surgical (STAA): Evaluating Valuation Following Recent Share Price Surge - Yahoo
Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical - GlobeNewswire
Why STAAR Surgical Company stock could rally in 2025Earnings Recap Summary & Daily Entry Point Alerts - newser.com
27.5% Holder Broadwood Releases 81-Page Brief Urging STAAR Surgical Vote Against Alcon Deal - Stock Titan
How hedge fund analytics apply to STAAR Surgical Company stockWeekly Market Report & Safe Capital Preservation Plans - newser.com
Comparing STAAR Surgical Company in custom built stock radarsTrade Performance Summary & Comprehensive Market Scan Reports - newser.com
BUYOUT INVESTIGATION: Does $28.00 Per Share Buyout Offer Shortchange STAAR Surgical Company (NASDAQ: STAA) Shareholders? Kaskela Law LLC is Investigating the Buyout Offer and Encourages STAA Shareholders to Contact the Firm - PR Newswire
Combining price and volume data for STAAR Surgical CompanyTrade Analysis Report & Community Consensus Trade Alerts - newser.com
Alcon, STAAR Surgical see US antitrust waiting period expire - MLex
Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon’s Acquisition of STAAR - MarketScreener
$1.5B Eye Care Merger Progresses: Alcon's Premium Buyout of STAAR Surgical Clears Key Regulatory Hurdle - Stock Titan
Broadwood files definitive proxy, STAAR reaffirms Alcon merger - Investing.com
Broadwood files definitive proxy, STAAR reaffirms Alcon merger By Investing.com - Investing.com UK
Alcon: Seeing Is Believing As Buyout Of STAAR Surgical Hangs In Balance (NYSE:ALC) - Seeking Alpha
Staar Surgical Co Stock (STAA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):